Navigation Links
Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
Date:5/7/2013

MT. VERNON, Wash., May 7, 2013 /PRNewswire/ -- Provitro Biosciences LLC (or "Provitro"), a subsidiary of Pendrell Corporation (NASDAQ: PCO) today received a patent from the United States Patent and Trademark Office covering foundational technologies that enable the rapid, disease-free, and high volume production of bamboo plants for the first time.   The patent issued today reflects more than a decade of innovative research by Provitro in the field of non-genetically modified commercial-scale plant propagation methods.

Provitro was awarded U.S. Patent No. 8435789, "Media, Kits, Systems and Methods for the Micropropagation of Bamboo," which focuses on methods of propagating bamboo by including certain plant growth regulators in the medias used for initiating bamboo shoots from plant explants and then rapidly multiplying the number of shoots.  This key innovation is the result of years of intensive research and development that for the first time enables the production of numerous, healthy bamboo plants for large-scale field plantings, including for the ornamental and timber bamboo industries. 

"The technology developed by Provitro lays the foundation for serving vast global markets with a reliable, economical and environmentally beneficial source of alternative fiber that has previously not been available on a commercial scale," commented Jackie Heinricher , chief executive officer of Provitro Biosciences.  "This patent reflects years of groundbreaking research efforts by the Provitro team, and underscores the potential we see in this technology."  

In addition to this issued U.S. patent, Provitro Biosciences has a large, active intellectual property portfolio for the worldwide protection of its proprietary technologies.  The company anticipates that this is just the first of many utility and Plant Patents to be issued for it's unique plant propagation methods and plant germplasms covering a wide variety of useful plant species in addition to bamboo.

ABOUT PROVITRO BIOSCIENCES
Founded as Booshoot in 2004, Provitro has developed a proprietary method to enable lower cost and higher quality commercial-scale plant production. Provitro is a world leader in bamboo propagation technologies. Provitro is producing giant timber bamboo starts, helping develop a sustainable fiber replacement for the pulp, paper, energy, textile and hardwood markets.  The company's headquarters, research and development laboratories and commercial production facilities are in Mt. Vernon, Washington.  For more information, visit www.provitrobio.com.

ABOUT PROVITRO™ TECHNOLOGY
Provitro™ technology involves propagating plants in a lab on a mass scale, as an alternative to traditional seed or genetically modified plantings.  The technology has the potential to be applied to a wide range of product segments in the forestry, pulp, textile, agriculture and horticultural sectors. Advantages of Provitro™ include:

  • A natural and green approach for commercial propagation that is not based on increased pesticide use or genetic modification;
  • Reduced risk of disease, pests, and pathogens;
  • The ability to produce plants such as bamboo that are difficult to propagate at scale with existing technologies; and
  • An opportunity to produce plants with particularly desirable characteristics, including vigor and growth rates that are faster than traditional sources of wood, pulp and fiber.

ABOUT PENDRELL
Pendrell Corporation, through its subsidiaries, is a fully integrated intellectual property (IP) investment, advisory services and asset management firm. Pendrell seeks to invest in or acquire companies or assets that represent unique, foundational intellectual property rights with outstanding growth potential. Pendrell is headquartered in Kirkland, Washington, with offices in Berkeley, Los Angeles and Washington, DC. For more information, visit www.pendrell.com.


'/>"/>
SOURCE Pendrell Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
2. Quanta BioSciences qRT-PCR technology recommended in newly published CDC protocol for detection of H7N9 Avian Influenza
3. Centrillion Biosciences Announces Next-Gen Sequencing Innovation Grant Program
4. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
5. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
6. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
7. Northstar Biosciences Launches All Natural Skincare Solutions
8. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
9. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research, Co-Invest in Sanguine BioSciences
10. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research with Seed Round Investment in Sanguine BioSciences
11. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Symic Bio, a biopharmaceutical company focused on ... therapeutics, announced today the completion of enrollment for the ... The trial will evaluate the safety and efficacy of ... of restenosis following angioplasty. "We,re pleased ... said Nathan Bachtell , M.D., Chief Medical Officer ...
(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... -- China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or ... China, today announced its financial results for the fourth quarter ... 2016 Financial Highlights Total sales in ... terms, or increased by 13.6% in USD terms to $77.6 ... Gross profit increased by 13.3% to $46.8 ...
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
Breaking Biology Technology:
(Date:2/8/2017)... -- Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion ... at a compound annual growth rate (CAGR) of 24.0% through ... markets for synthetic biology. - Analyses of global market trends, ... compound annual growth rates (CAGRs) through 2021. - Coverage of ...
(Date:2/7/2017)... Feb. 7, 2017   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... its innovative, highly flexible and award winning eClinical solution, ... iMedNet is a proven Software-as-a-Service (SaaS) clinical ... Capture (EDC), but also delivers an entire suite of ...
(Date:2/6/2017)... 2017 According to Acuity Market Intelligence, ... authorities to continue to embrace biometric and digital ... Automated Border Control (ABC) eGates and 1436 Automated ... than 163 ports of entry across the globe. ... a combined CAGR of 37%. APC Kiosks reached ...
Breaking Biology News(10 mins):